Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
Dan Douer, Ibrahim Aldoss, Matthew A Lunning, et al.
Haematologica
|
March 20, 2025
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel
Emily Curran, Marlise R Luskin, Houda Alachkar, et al.
Leukemia Research
|
September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
John Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
British Journal of Haematology
|
November 6, 2024
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes
Jose Tinajero, Sharon Xu, Dat Ngo, et al.
Leukemia Research
|
July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
Justin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
Francis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Blood Advances
|
October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
Chezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab
Todd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2016
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
Chezi Ganzel, Judith Manola, Dan Douer, et al.
Haematologica
|
October 15, 2020
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia
Mark B Geyer, Ellen K Ritchie, Arati V Rao, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
Dan Douer, Ibrahim Aldoss, Matthew A Lunning, et al.
Haematologica
|
March 20, 2025
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel
Emily Curran, Marlise R Luskin, Houda Alachkar, et al.
Leukemia Research
|
September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
John Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
British Journal of Haematology
|
November 6, 2024
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes
Jose Tinajero, Sharon Xu, Dat Ngo, et al.
Leukemia Research
|
July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
Justin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
Francis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Blood Advances
|
October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
Chezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab
Todd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2016
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
Chezi Ganzel, Judith Manola, Dan Douer, et al.
Haematologica
|
October 15, 2020
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia
Mark B Geyer, Ellen K Ritchie, Arati V Rao, et al.
Page
of 9